NCT00390624View on ClinicalTrials.gov

Prevention Of Nephrotoxicity Following Bone Marrow Transplantation Using Urodilatin and Mannitol

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

July 31, 2003

Primary Completion Date

December 31, 2006

Study Completion Date

December 31, 2006

Conditions
Renal DysfunctionAcute Renal FailureMortality
Interventions
DRUG

URODILATIN (ULARITIDE, ATRIAL NATRIURETIC PEPTIDE)

DRUG

MANNITOL

Trial Locations (1)

80218

Rocky Mountain Cancer Centers 1800 Williams Street, Suite 200, Denver

All Listed Sponsors
collaborator

University of Colorado, Denver

OTHER

lead

Rocky Mountain Cancer Centers

OTHER

NCT00390624 - Prevention Of Nephrotoxicity Following Bone Marrow Transplantation Using Urodilatin and Mannitol | Biotech Hunter | Biotech Hunter